Skip to main content
| News

BeiGene opens European headquarters in Basel

19.05.2022

BeiGene has opened its new European headquarters in Basel. The global biotech specializing in innovative cancer treatments intends to build on European growth out of Basel and its office will initially include 150 employees.

At the opening event: Christof Klöpper, CEO of Basel Area Business & Innovation, talks while John V. Oyler (seated far right), CEO of BeiGene, listens attentively (img: Annelise Michel)

Basel is joining Cambridge, Massachusetts, and Beijing, China, as a location of one of the main regional offices of BeiGene. According to a press release, the biotech’s European organization currently includes more than 270 employees. The Basel office will become a hub for BeiGene’s operations in Europe and initially employ 150 members of staff.

“The skilled talent network in Basel will support our future growth,” said John V. Oyler, Co-Founder, Chairman and CEO at BeiGene. And this is “just the beginning” of growth plans in Europe.

BeiGene is a global, commercial-stage, research-based biotechnology company focused on molecularly-targeted and immuno-oncology cancer therapeutics. Its internal pipeline reportedly consists of 40 novel oral small molecules and monoclonal antibodies for cancer.

“Basel is the biotech hub of continental Europe“

At the opening event of BeiGene Switzerland GmbH, Deborah Strub, Member of the Executive Board and Head of the Cluster & Initiatives Department at the Chamber of Commerce of the two Basel cantons, said “BeiGene’s presence also represents a great opportunity for the Swiss and particularly the Basel economy”. Gerwin Winter, Head of Europe at BeiGene, commented “our new European headquarters in Basel will further strengthen our position and will be a catalyst for changing the lives of European patients.”

Christof Klöpper, CEO of Basel Area Business & Innovation, also welcomes the opening of the new offices. In an article in the Basler Zeitung newspaper he is quoted as saying “Basel is the biotech hub of continental Europe. In recent years we have worked hard to promote this message – to the USA and also China“.

Share this article

Sign up to receive our newsletter in your inbox.

You may also be interested in

Basel Area Business & Innovation, Innovation, Invest, Life Sciences / biotech, Switzerland Innovation Park

South Korean pharma firms show interest in the Basel Area

Several South Korean firms from the life sciences industry, including three pharmaceutical multinationals, have visited the Basel Area on fact-finding...

Read More
Gamma Technologies acquires ProFEMAG portfolio
Advanced Manufacturing/AI, Basel Area Business & Innovation, ICT, Innovation, Invest

Gamma Technologies acquires ProFEMAG portfolio

The Basel-based firm ProFEMAG AG has sold its FEMAG software for electrical machine applications to Gamma Technologies. The company based...

Read More
Basel Area Business & Innovation, ICT, Innovation, Invest, Life Sciences / biotech

Databaum establishes headquarters in Basel

Databaum is establishing its headquarters in Basel and plans to grow from its location there. The startup provides the agricultural...

Read More
Clinerion launches patient information platform
Basel Area Business & Innovation, Digital Health, ICT, Innovation, Invest, Life Sciences / biotech

Clinerion launches patient information platform

Basel-based Clinerion is introducing its machine learning platform. It comprises a global network of hospitals and enables researchers to recognize...

Read More
Basel Area Business & Innovation, Innovation, Invest, Life Sciences / biotech, Switzerland Innovation Park

New innovation campus opens in the Basel Area

The Main Campus of the Switzerland Innovation Park Basel Area was officially opened on October 29. In his speech, Federal...

Read More
Sumitovant acquires all shares in Myovant
Basel Area Business & Innovation, Innovation, Invest, Life Sciences / biotech

Sumitovant acquires all shares in Myovant

Sumitovant is in the process of making Basel-based Myovant Sciences a wholly owned subsidiary by acquiring a 100 percent shareholding...

Read More
1 2 3 59

Do you have a question? We'd like to hear from you.